TrialJournal for immunotherapy of cancer2023

First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial.

Lisa Paschold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.